cAMPfield Therapeutics, a San Diego biotech working on inflammatory and immunology medicines, raised an $180 million Series A, according to the report. The company’s financing highlights continued investor appetite for immunology platforms, particularly those licensed from other companies and aimed at leveraging proven biological pathways. The round also reflects how late-stage conviction is being matched with early platform bets in inflammation and immune modulation, where biomarker strategy and translational readouts can accelerate de-risking. For the sector, the funding adds another large check to an immunology-heavy pipeline landscape as companies compete to convert mechanistic differentiation into registrational trial momentum.